Welcome to our dedicated page for Edgewell Pers Care Co SEC filings (Ticker: EPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edgewell Personal Care Company (NYSE: EPC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Edgewell manages its personal care portfolio, finances and governance, and they are a key resource for anyone analyzing EPC stock.
Investors can review annual reports on Form 10-K for comprehensive discussions of Edgewell’s business, risk factors and performance across its Wet Shave, Sun and Skin Care and Feminine Care segments. Quarterly reports on Form 10-Q update these disclosures with more frequent financial and operational information, including segment results and commentary on market conditions, tariffs and foreign exchange impacts.
Edgewell also files current reports on Form 8-K to describe material events. Recent 8-K filings have covered quarterly and annual earnings releases and the asset purchase agreement to sell the Feminine Care business to Essity, including key terms and closing conditions. These filings help investors track significant strategic decisions, restructuring actions and leadership changes.
The company’s definitive proxy statement on Schedule 14A (DEF 14A) outlines board composition, governance practices, executive compensation programs, shareholder proposals and the agenda for the annual meeting. It also includes management’s discussion of strategy, portfolio transformation and recognition for sustainability and workplace achievements.
On Stock Titan, Edgewell’s filings are supplemented with AI-powered summaries that explain the main points of lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements in clear language. Real-time updates from EDGAR ensure new filings appear promptly, while specialized views make it easier to locate items such as insider transaction reports on Form 4, stock incentive plan details and other disclosures relevant to EPC shareholders.
Brandes Investment Partners, L.P. reports beneficial ownership of 6,121,589 common shares of Edgewell Personal Care Co., representing 13.1% of the class as of the reported date.
Brandes has shared voting power over 4,112,649 shares and shared dispositive power over all 6,121,589 shares, with no sole voting or dispositive authority. The firm files as an investment adviser and certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of Edgewell.
Edgewell Personal Care reported first‑quarter fiscal 2026 net sales of $422.8 million, up 1.9% year over year, but swung to a much larger loss. From continuing operations, the company posted a net loss of $29.2 million, with total net loss of $65.7 million including discontinued operations.
Results were hit by $18.1 million of restructuring charges and $5.8 million of related costs, plus a $37.4 million goodwill impairment and $3.8 million loss on assets held for sale tied to the divestiture of the Feminine Care segment. Gross profit fell to $161.0 million and gross margin declined as inflation, tariffs and lower volume outweighed productivity savings.
Wet Shave sales slipped to $291.3 million and segment profit declined to $42.2 million, while Sun and Skin Care sales rose 9.0% to $131.5 million but remained slightly unprofitable. Operating cash flow was negative $125.9 million, and total borrowings reached $1.56 billion, including $277.0 million drawn on the U.S. revolver. The sale of Feminine Care to Essity for about $340 million closed after quarter‑end and is earmarked primarily for debt reduction and reinvestment.
Edgewell Personal Care Co. director Sit Swan reported an equity grant. On February 5, 2026, the director was awarded 7,817 restricted stock equivalents at a price of $0 per unit, held directly.
These restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual shareholder meeting, unless the director elects to defer conversion until service on the Board ends.
Edgewell Personal Care Company director Rakesh Sachdev reported an equity award in the form of derivative securities. On February 5, 2026, he received 7,817 restricted stock equivalents at a price of $0 per unit, all held as a direct ownership position.
According to the filing, these restricted stock equivalents are designed to convert into the same number of shares of Edgewell common stock on the day preceding the next annual meeting of shareholders, unless Sachdev elects to defer conversion until his service on the Board of Directors ends. After this transaction, he beneficially owns 7,817 derivative securities tied to Edgewell common stock.
Edgewell Personal Care director Stephanie Stahl reported a new equity grant. On February 5, 2026, she acquired 7,817 restricted stock equivalents at a price of $0 per unit. These are derivative securities that track the value of Edgewell common stock.
The restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual meeting of shareholders, unless Stahl elects to defer conversion until her service on Edgewell’s Board of Directors ends. After this grant, she beneficially owned 7,817 derivative units directly.
Edgewell Personal Care Company director receives equity grant. Director John C. Hunter III was granted 7,817 restricted stock equivalents of Edgewell common stock at a price of $0 on 02/05/2026. These restricted stock equivalents convert into common shares on the day before the next annual shareholder meeting, unless he elects to defer conversion until his service on the Board ends.
Edgewell Personal Care Company director Corbin George reported receiving 7,817 restricted stock equivalents on February 5, 2026. These derivative securities were acquired at a price of $0 and are held as direct ownership.
According to the filing, the restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual meeting of shareholders, unless the director elects to defer conversion until service on the Board ends.
Edgewell Personal Care Company director equity grant
Edgewell Personal Care Company reported that director Gary Waring received an award of 7,817 restricted stock equivalents on February 5, 2026. These derivative securities were granted at a price of $0 per unit and are held in his direct ownership.
The restricted stock equivalents convert into shares of Edgewell common stock on the day preceding the next annual meeting of shareholders, unless Waring elects to defer conversion until his service on Edgewell’s Board of Directors ends. After this grant, he beneficially owns 7,817 restricted stock equivalents.
Edgewell Personal Care director Carla C. Hendra received 7,817 restricted stock equivalents on February 5, 2026. These derivative awards carry a stated price of $0 per unit and are held directly. They are designed to convert into shares of Edgewell common stock on a future date.
The restricted stock equivalents convert into common shares on the day before the next annual shareholder meeting, unless the director chooses to defer conversion until service on the Board of Directors ends. After this grant, 7,817 derivative securities are beneficially owned.
Edgewell Personal Care Company director receives equity award. Director Robert William Black was granted 7,817 restricted stock equivalents on February 5, 2026 at a price of $0 per unit. Following this grant, he beneficially owns 7,817 derivative securities directly.
The restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual shareholder meeting, unless Black elects to defer conversion until his Board service ends.